Form 4: Tarsus Pharmaceuticals Executive Acquires Stock Options and Restricted Stock Units

Bryan Wahl, General Counsel of Tarsus Pharmaceuticals, reports acquisition of stock options and restricted stock units.

Summary

• Bryan Wahl, the General Counsel of Tarsus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 5, 2025, Wahl acquired stock options for 30,628 shares at an exercise price of $44.54.
• These options vest 25% on March 5, 2026, and then 1/48th monthly for the following three years, contingent upon continuous service.
• Wahl also acquired 20,089 Restricted Stock Units (RSUs) on the same date.
• These RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to continuous service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction report. The vesting schedule suggests a long-term commitment, which is mildly positive.

Positives

• The acquisition of stock options and RSUs suggests confidence in the company's future performance from a key executive.

Future Outlook

The vesting schedules for both the stock options and RSUs are contingent upon the Reporting Person's continuous service.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's view of the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry.
• Vesting schedules are generally structured to incentivize long-term commitment and performance, similar to practices at companies like Alcon or Bausch + Lomb.

Stakeholder Impact

• The transaction could be viewed positively by shareholders as it aligns the executive's interests with the company's long-term success.

Key Dates